Skip to content
approvedCardiovascular

Captopril

Also known as: Capoten, D-2-methyl-3-mercaptopropanoyl-L-proline, SQ 14225

Captopril is the first orally active angiotensin-converting enzyme (ACE) inhibitor, developed from the study of bradykinin-potentiating peptides found in the venom of the Brazilian pit viper Bothrops jararaca. FDA-approved in 1981, it revolutionized the treatment of hypertension and heart failure and established an entirely new class of cardiovascular drugs. Captopril remains one of the most important examples of venom-derived pharmaceutical development in medical history.

3 cited references·5 researched benefits

Quick Answer

Captopril (Capoten) is the first oral ACE inhibitor, derived from study of Brazilian pit viper venom peptides. FDA-approved in 1981, it blocks angiotensin-converting enzyme to reduce angiotensin II production, lowering blood pressure and reducing cardiac workload. It transformed cardiovascular medicine by establishing the entire ACE inhibitor drug class. Though largely supplanted by longer-acting ACE inhibitors like lisinopril and enalapril, captopril remains a landmark venom-to-drug success story and is still used clinically.

Key Facts

Mechanism
Captopril competitively inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This reduces aldosterone secretion (decreasing sodium and water retention), increases bradykinin levels (promoting vasodilation via nitric oxide and prostacyclin), and reduces sympathetic nervous system activity. The net effect is decreased peripheral vascular resistance, reduced blood pressure, decreased cardiac preload and afterload, and inhibition of pathological cardiac remodeling. Its sulfhydryl group provides unique free-radical scavenging properties not shared by other ACE inhibitors.
Research Status
approved
Half-Life
~2 hours
Molecular Formula
C₉H₁₅NO₃S
Primary Use
Cardiovascular
Table of Contents

Benefits

  • Effective blood pressure reduction — lowers systolic/diastolic by 10–15/5–10 mmHg as monotherapystrong
  • Mortality reduction in heart failure — landmark SAVE trial demonstrated 19% reduction in all-cause mortality post-MIstrong
  • Renal protection in diabetic nephropathy — slows progression of proteinuria and renal function decline in type 1 diabetesstrong
  • Rapid onset of action — peak effect within 60–90 minutes, useful for hypertensive urgencystrong
  • Unique sulfhydryl-mediated antioxidant and cardioprotective properties not shared by other ACE inhibitorsmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Oral25–50 mg2–3× dailyStandard hypertension dosing. Take 1 hour before meals for optimal absorption. Maximum 450 mg/day.
Oral6.25–12.5 mg3× dailyHeart failure initiation dose. Start low and titrate upward every 2 weeks as tolerated. Target dose 50 mg three times daily.
Oral (sublingual)25 mgSingle doseSublingual administration for hypertensive urgency. Onset within 15–30 minutes. Monitor closely for excessive hypotension.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Dry cough — class effect of ACE inhibitors due to bradykinin accumulation, affecting 5–20% of patientscommon
  • Dysgeusia (altered taste sensation) — more common with captopril than other ACE inhibitors due to sulfhydryl groupcommon
  • Hypotension — especially with first dose or in volume-depleted patientscommon
  • Hyperkalemia — risk increased with renal impairment, potassium-sparing diuretics, or potassium supplementsrare
  • Angioedema — rare but potentially life-threatening swelling of face, lips, tongue, or airwayserious
  • Neutropenia/agranulocytosis — rare, primarily in patients with collagen vascular disease or renal impairmentserious

Frequently Asked Questions

How was captopril developed from snake venom?
In the 1960s, Brazilian pharmacologist Sergio Ferreira discovered that venom from the pit viper Bothrops jararaca contained peptides that potentiated bradykinin and inhibited ACE. John Vane's group at the Royal College of Surgeons further characterized these bradykinin-potentiating peptides (BPPs). Miguel Ondetti and David Cushman at Squibb then used X-ray crystallography of the ACE active site to design captopril as a small-molecule inhibitor mimicking these venom peptides. It was approved by the FDA in 1981, launching the ACE inhibitor drug class.
Why has captopril been largely replaced by newer ACE inhibitors?
Captopril requires 2–3 times daily dosing due to its short half-life (~2 hours), while newer ACE inhibitors like lisinopril, enalapril, and ramipril offer once- or twice-daily dosing with better patient adherence. Captopril's sulfhydryl group also causes a higher incidence of taste disturbances and skin rash compared to non-sulfhydryl ACE inhibitors. However, captopril's rapid onset makes it still useful for hypertensive urgency, and it remains on the WHO List of Essential Medicines.
Is captopril still used today?
Yes, though less commonly than longer-acting ACE inhibitors. Captopril is still used for hypertensive urgency (sublingual administration provides rapid blood pressure reduction), post-myocardial infarction management when rapid ACE inhibition is desired, and in settings where medication costs are a consideration since generic captopril is inexpensive. It remains on the WHO Model List of Essential Medicines and is widely available globally.

References

  1. 1
    A new class of angiotensin-converting enzyme inhibitors (captopril)(1977)PubMed ↗
  2. 2
    Effects of enalapril, captopril, and their combination in postinfarction left ventricular dysfunction(1990)PubMed ↗
  3. 3
    Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction (SAVE trial)(1992)PubMed ↗

Latest Research

Last updated: 2026-02-19